Bayer AG: Putting Down Bucks
This article was originally published in Start Up
Executive Summary
Bayer AG is expanding its investment in the US, focusing particularly on its health care businesses. It plans to spend $5.1 billion on pharmaceutical research in the next 4-5 years in the US, adding 200 scientists and building a huge new facility near its existing labs in Connecticut. Some of the money will go to outside companies, as well.
You may also be interested in...
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Building Long-Term Value Into Near-Term Commercial Strategy
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.
Optimistic About Cancer Immunotherapy, Downbeat About Costs
While cancer experts are almost giddy with enthusiasm about rapid advances in cancer immunotherapy—in a field not known for euphoria--they are equally pessimistic about market access hurdles as impediments to improved patient care and are seeking manageable approaches to assessing value.